Core summary of product characteristics for human normal immunoglobulin for intravenous administration (IVIg)

  • Email
  • Help
Current effective version

Revision 4 - Adopted guideline

Currently under revision - see below

Reference numberCHMP/BPWP/94038/2007 Rev. 4
Published18/12/2012
Effective from01/07/2013
KeywordsIntravenous immunoglobulin (IVIg), primary immunodeficiency syndromes, hypogammaglobulinaemia, primary immune thrombocytopenia, idiopathic thrombocytopenic purpura (ITP), Guillain Barré syndrome, Kawasaki disease, multifocal motor neuropathy (MMN), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), myasthenia gravis exacerbations
DescriptionThis document describes the information to be included in the summary of product characteristics for human normal immunoglobulins for intravenous administration.


Document history

Revision 5

In progress

Draft guideline

 

 

Published: 22/12/2016

 

Deadline for comments: 31/03/2017

Superseding documentConcept paperPublished: 01/08/2014

Revision 4 

Current version

Adopted guideline


 
In operation: 01/07/2013–present
Revision 3

Adopted guideline


Overview of comments


Draft guideline


Concept paper

In operation: 01/05/2011–30/06/2013


Published: 06/12/2010


Published: 06/02/2009


Published: 16/03/2005

Revision 2 Adopted guidelineIn operation: 01/11/2004–30/04/2011


Related content


How helpful is this page?

Average rating:

 Based on 0 ratings

Add your rating:

See all ratings
0 ratings
0 ratings
0 ratings
0 ratings
0 ratings
    

Tell us more